NASDAQ:INBX

Inhibrx - INBX News Today

$27.25

+0.16 (+0.59%)

(As of 12/7/2022 12:00 AM ET)

Add

Compare

Today's Range: $26.85
▼
$28.43
50-Day Range: $17.49
▼
$33.33
52-Week Range: $7.67
▼
$45.99

Volume: 374,502 shs
Average Volume: 488,636 shs
Market Capitalization: $1.19 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $46.50

Get Inhibrx News Delivered to You Automatically

INBX Media Mentions By Week

INBX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

INBX
News Sentiment
▼
0.00

0.46
▲
Average
Medical
News Sentiment

INBX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

INBX Articles
This Week
▼
2

1
▲
INBX Articles
Average Week

Source

Source	Headline
	Insider Selling: Inhibrx, Inc. (NASDAQ:INBX) Insider Sells 40,000 Shares of Stock marketbeat.com - December 7 at 6:46 PM
	Inhibrx's drug for rare bone cancer shows promise in ongoing phase 1 study seekingalpha.com - November 16 at 6:22 PM
	Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma finance.yahoo.com - November 16 at 6:22 PM
	Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate finance.yahoo.com - November 16 at 6:22 PM
	Inhibrx Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag finance.yahoo.com - November 9 at 9:44 AM
	Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights finance.yahoo.com - November 8 at 8:29 AM
	Inhibrx, Inc. (INBX) Reports Q3 Loss, Misses Revenue Estimates finance.yahoo.com - November 8 at 8:29 AM
	Inhibrx Announces Participation in Upcoming Scientific Conferences finance.yahoo.com - October 20 at 5:15 PM
	$40 Million Bet On Inhibrx? 3 Stocks Insiders Are Buying msn.com - October 13 at 12:48 PM
	Investors in Inhibrx (NASDAQ:INBX) have unfortunately lost 18% over the last year finance.yahoo.com - October 13 at 7:34 AM
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
	Inhibrx's Experimental Drug For Inherited Disease Capable For Accelerated FDA Approval, Shares Surge finance.yahoo.com - October 12 at 9:10 AM
	Why Is Inhibrx (INBX) Stock Soaring 45% Today? investorplace.com - October 4 at 5:02 PM
	Inhibrx stock soars 33% on potential accelerated approval path for INBRX-101 after FDA discussions seekingalpha.com - October 4 at 4:40 PM
	Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study finance.yahoo.com - October 4 at 10:14 AM
	Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency finance.yahoo.com - October 3 at 6:23 PM
	Increasing losses over year doesn't faze investors as stock advances 7.1% this past week nasdaq.com - August 16 at 12:38 AM
	European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma finance.yahoo.com - August 16 at 12:38 AM
	Inhibrx, Inc. (INBX) Reports Q2 Loss, Lags Revenue Estimates finance.yahoo.com - August 9 at 1:54 AM
	Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights finance.yahoo.com - August 8 at 8:53 PM
	Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance finance.yahoo.com - June 30 at 10:26 AM
	Inhibrx: Potential To Move To Registration Study With INBRX-101 (NASDAQ:INBX) - Seeking Alpha seekingalpha.com - June 10 at 4:12 PM
	Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting - Yahoo Finance finance.yahoo.com - May 20 at 8:56 AM
	Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting finance.yahoo.com - May 19 at 5:54 PM
	Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder - Benzinga - Benzinga benzinga.com - May 18 at 8:29 PM
	Form 8-K Inhibrx, Inc. For: May 16 - StreetInsider.com streetinsider.com - May 18 at 3:29 PM
	Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences - Yahoo Finance finance.yahoo.com - May 18 at 7:23 AM
	Steering committee of pulmonary and primary care experts aims to reduce time to diagnose complex lung diseases - Yahoo Finance finance.yahoo.com - May 17 at 10:50 AM
	Inhibrx Reports Co.'s INBRX-101 Showed Favorable Safety Profile In Patients With Alpha-1 Antitrypsin Defi - Benzinga benzinga.com - May 16 at 7:48 PM
	Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder finance.yahoo.com - May 16 at 7:48 PM
	Inhibrx stock falls despite INBRX-101 shows safety in early-stage study in genetic disease - Seeking Alpha seekingalpha.com - May 16 at 2:13 PM
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
	INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing finance.yahoo.com - May 16 at 2:13 PM
	Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq nasdaq.com - May 11 at 8:32 AM
	Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights finance.yahoo.com - May 9 at 7:58 PM
	The 17% return this week takes Inhibrx's (NASDAQ:INBX) shareholders one-year gains to 25% finance.yahoo.com - May 5 at 8:36 AM
	Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock? finance.yahoo.com - May 3 at 6:55 PM
	Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting finance.yahoo.com - April 5 at 6:38 PM
	Inhibrx, Inc. Common Stock (INBX) nasdaq.com - March 29 at 7:28 PM
	Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting finance.yahoo.com - March 24 at 7:45 PM
	SMBC Nikko Initiates Coverage On Inhibrx with Outperform Rating, Announces Price Target of $40 benzinga.com - March 16 at 3:25 PM
	Inhibrx initiated as outperform at SMBC Nikko; sees 98% upside seekingalpha.com - March 16 at 3:25 PM
	Inhibrx Gets FDA Orphan Designation for INBRX-101 in AATD >INBX marketwatch.com - March 3 at 3:03 PM
	Inhibrx's INBRX-101 for AAT deficiency gets FDA's orphan drug designation seekingalpha.com - March 3 at 3:03 PM
	Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency finance.yahoo.com - March 3 at 3:03 PM
	Inhibrx Selects Genialis ResponderID™ for Clinical Optimization Study of INBRX-109 nz.finance.yahoo.com - February 28 at 5:57 PM
	Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights finance.yahoo.com - February 28 at 5:55 PM
	Inhibrx Announces Amended Loan Agreement with Oxford finance.yahoo.com - February 22 at 6:09 PM
	Investors one-year losses grow to 31% as the stock sheds US$100m this past week nasdaq.com - February 14 at 1:50 PM
	Inhibrx falls after announcing resignation of medical chief seekingalpha.com - January 25 at 10:42 AM
	Relative Strength Alert For Inhibrx nasdaq.com - January 13 at 1:03 PM
	Inhibrx Announces Initial Phase 1 Dose Escalation Results For INBRX-106 In Combination With Keytruda Along With Updated Single Agent Data benzinga.com - January 6 at 9:48 AM
	Inhibrx Shares Interim Data On INBRX-106 - Keytruda Combo Therapy In Solid Tumors markets.businessinsider.com - January 5 at 8:28 AM

Get Inhibrx News Delivered to You Automatically

This page (NASDAQ:INBX) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Inhibrx - INBX News Today

INBX Media Mentions By Week

INBX Media Sentiment

INBX News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info